Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (691-700 of 849) with videos related to

Pageof 85
Sort By:
Hepatology (Baltimore, Md.)|August 24, 2017
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinomaTasnuva D Kabir, Clarissa Ganda, Rikki M Brown, et al.
Metabolism: Clinical and Experimental|August 1, 2023
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center studyMatina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, et al.
Scandinavian Journal of Gastroenterology|July 11, 2018
Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histologyTea Lund Laursen, Cecilie Brøckner Siggard, Konstantin Kazankov, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionJanett Fischer, Stephan Böhm, Markus Scholz, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
ERJ Open Research|June 9, 2021
The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workersHani Abo-Leyah, Stephanie Gallant, Diane Cassidy, et al.
Journal of Clinical and Translational Hepatology|May 19, 2021
Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver DiseaseWen-Yue Liu, Mohammed Eslam, Kenneth I Zheng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2018
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesZobair Younossi, Maria Stepanova, Janus P Ong, et al.
Hepatology International|March 20, 2015
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsMaria Buti, Scott Fung, Edward Gane, et al.
Diabetes Care|April 5, 2020
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM TrialJagdeep S S Singh, Ify R Mordi, Keeran Vickneson, et al.
Pageof 85

Showing results (691-700 of 849) with videos related to

Sort By:
Pageof 85
Hepatology (Baltimore, Md.)|August 24, 2017
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinomaTasnuva D Kabir, Clarissa Ganda, Rikki M Brown, et al.
Metabolism: Clinical and Experimental|August 1, 2023
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center studyMatina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, et al.
Scandinavian Journal of Gastroenterology|July 11, 2018
Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histologyTea Lund Laursen, Cecilie Brøckner Siggard, Konstantin Kazankov, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionJanett Fischer, Stephan Böhm, Markus Scholz, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
ERJ Open Research|June 9, 2021
The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workersHani Abo-Leyah, Stephanie Gallant, Diane Cassidy, et al.
Journal of Clinical and Translational Hepatology|May 19, 2021
Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver DiseaseWen-Yue Liu, Mohammed Eslam, Kenneth I Zheng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 17, 2018
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesZobair Younossi, Maria Stepanova, Janus P Ong, et al.
Hepatology International|March 20, 2015
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsMaria Buti, Scott Fung, Edward Gane, et al.
Diabetes Care|April 5, 2020
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM TrialJagdeep S S Singh, Ify R Mordi, Keeran Vickneson, et al.
Pageof 85